What is iBio?
iBio is at the forefront of developing next-generation cardiometabolic and obesity therapeutics. The company's innovative approach aims to enhance weight loss quality by focusing on muscle preservation, metabolic function improvement, and long-term treatment adherence through convenient dosing and superior tolerability, while also serving as a complement to existing therapeutic options. Beyond its cardiometabolic focus, iBio is advancing a preclinical immuno-oncology pipeline targeting challenging solid tumors, including those in breast, lung, colorectal, pancreatic cancer, and glioblastoma. The company leverages a sophisticated machine-learning-driven antibody discovery platform, offering core services such as precision epitope engineering, access to a proprietary fully human antibody library, antibody optimization via its StableHu technology, next-generation bispecific design through its EngageTx T-cell engager panel, and enhanced safety and developability with its ShieldTx masking system. The company is steered by Martin Brenner, DVM, Ph.D., who serves as Chief Executive Officer and Chief Scientific Officer.
How much funding has iBio raised?
iBio has raised a total of $6.5M across 2 funding rounds:
Debt
$350K
Other Financing Round
$6.2M
Debt (2020): $350K with participation from PPP
Other Financing Round (2025): $6.2M, investors not publicly disclosed
Key Investors in iBio
PPP
Public-Private Partnership
What's next for iBio?
The substantial enterprise-level funding, highlighted by the recent strategic investment, positions iBio for accelerated development and market penetration. This capital infusion is expected to fuel the advancement of its novel cardiometabolic and obesity therapeutics, as well as its promising immuno-oncology pipeline. The company's proprietary technology platforms, including its machine-learning-driven antibody discovery and optimization systems, are key differentiators that will likely be leveraged to expedite preclinical and clinical trials. Strategic partnerships and further financing rounds may be anticipated as iBio progresses through its development milestones, aiming to solidify its position as a leader in innovative biopharmaceutical solutions.
See full iBio company page
